Two Sigma Securities LLC Has $212,000 Stake in Baxter International Inc. $BAX

Two Sigma Securities LLC cut its position in shares of Baxter International Inc. (NYSE:BAX) by 67.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,960 shares of the medical instruments supplier’s stock after selling 21,104 shares during the quarter. Two Sigma Securities LLC’s holdings in Baxter International were worth $212,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Baird Financial Group Inc. grew its holdings in Baxter International by 3.2% during the 2nd quarter. Baird Financial Group Inc. now owns 52,436 shares of the medical instruments supplier’s stock worth $1,588,000 after acquiring an additional 1,604 shares during the period. California State Teachers Retirement System boosted its position in shares of Baxter International by 2.9% during the 2nd quarter. California State Teachers Retirement System now owns 649,463 shares of the medical instruments supplier’s stock valued at $19,666,000 after purchasing an additional 18,439 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Baxter International by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier’s stock worth $231,304,000 after purchasing an additional 97,687 shares during the period. BI Asset Management Fondsmaeglerselskab A S grew its stake in Baxter International by 21.4% during the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 24,356 shares of the medical instruments supplier’s stock worth $737,000 after purchasing an additional 4,293 shares during the period. Finally, Captrust Financial Advisors increased its holdings in Baxter International by 5.5% in the second quarter. Captrust Financial Advisors now owns 53,933 shares of the medical instruments supplier’s stock worth $1,633,000 after purchasing an additional 2,813 shares in the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Price Performance

Shares of BAX opened at $25.81 on Friday. The stock has a market cap of $13.34 billion, a P/E ratio of -12.47, a P/E/G ratio of 3.87 and a beta of 0.60. The business’s fifty day moving average is $24.73 and its 200 day moving average is $20.72. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 1.39. Baxter International Inc. has a 12-month low of $15.73 and a 12-month high of $30.00.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.19. The firm had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. The business’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 earnings per share. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. Sell-side analysts anticipate that Baxter International Inc. will post 2.04 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Friday, August 28th will be issued a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, August 28th. Baxter International’s dividend payout ratio (DPR) is currently -1.93%.

Analysts Set New Price Targets

BAX has been the topic of a number of research analyst reports. Citigroup upgraded Baxter International from a “sell” rating to a “neutral” rating and increased their price target for the stock from $17.00 to $28.00 in a report on Friday, July 31st. TD Cowen lifted their price objective on shares of Baxter International from $20.00 to $24.00 and gave the company a “hold” rating in a research note on Monday, July 27th. UBS Group boosted their target price on shares of Baxter International from $19.00 to $25.00 and gave the company a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings raised shares of Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Finally, Stifel Nicolaus raised their price target on shares of Baxter International from $19.00 to $24.00 and gave the stock a “hold” rating in a report on Tuesday, July 28th. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $22.45.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.